You are here: Home » Current Affairs » Coronavirus » News
Business Standard

AstraZeneca expands Covid-19 vaccine supply tie-up with Oxford Biomedica

AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmaker's COVID-19 vaccine candidate

Topics
Coronavirus | Coronavirus Vaccine | Oxford University

Reuters 

Photo: Shutterstock

(Reuters) - AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmaker's COVID-19 vaccine candidate, in a deal that will pay the gene and cell therapy firm 15 million pounds ($20 million) upfront and an additional 35 million pounds plus other costs by the end of 2021.

Oxford Biomedica said in a statement that under the deal it would mass-produce the potential vaccine, AZD1222, for the novel for a period of 18 months, which may be further extended by another 18 months into 2022 and 2023.

 

 

($1 = 0.7458 pounds)

 

(Reporting by Pushkala Aripaka in Bengaluru; editing by Patrick Graham)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, September 01 2020. 14:17 IST
RECOMMENDED FOR YOU